Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Allakos Inc.
  6. Company
    ALLK   US01671P1003


Delayed Nasdaq  -  04:00:00 2023-02-08 pm EST
6.880 USD   -5.62%
2022Allakos Inc.(NasdaqGS:ALLK) added to S&P Biotechnology Select Industry Index
2022Allakos Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
2022Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
Business Summary
Logo Allakos Inc.
Allakos Inc. is a clinical stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It also developed a formulation of lirentelimab for subcutaneous (SC) administration. The Company is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

Number of employees : 192 people.
Name Title Age Since
Robert Alexander Chief Executive Officer & Director 52 2019
Adam Tomasi President & Chief Operating Officer 52 2021
Harlan Radford Chief Financial Officer - 2021
Ruby Casareno Vice President-Technical Operations - -
Craig Paterson Chief Medical Officer - 2021
Roland K. Winger Senior Vice President - 2017
Sally D. Bolmer, Dr. Vice President-Regulatory Affairs & Development - 2016
Members of the board
Name Title Age Since
Dan Janney Chairman 56 2017
John P. McKearn, Dr. Independent Director 68 2012
Steven P. James Independent Director 64 2016
Paul E. Walker Independent Director 47 2017
Robert E. Andreatta Independent Director 60 2018
Robert Alexander Chief Executive Officer & Director 52 2019
Amy L. Ladd, Dr. Director 64 2022
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 85,203,597 81,532,017 95.7% 0 0.0% 95.7%
Alta Partners Management Corp. 9,050,493 10.6%
Capital Research & Management Co. (World Investors) 6,614,358 7.76%
NEA Management Co. LLC 6,148,704 7.22%
Logos Global Management LP 5,936,666 6.97%
BVF Partners LP 5,006,921 5.88%
Capital Research & Management Co. (Global Investors) 4,912,458 5.77%
RiverVest Venture Management LLC 4,887,932 5.74%
Frazier Life Sciences Management LP 4,792,000 5.62%
Deep Track Capital LP 4,518,575 5.30%
Vivo Capital LLC 4,120,134 4.84%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Allakos Inc.